NCT02500407 2025-09-12A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Genentech, Inc.Phase 1/2 Completed713 enrolled 1 FDA